FinanceAsianet Newsable
CAPR Stock Eyes Worst Week Ever After FDA Panel Blow To Deramiocel — Retail Bulls Still See A Path To Approval
in5points
CAPR stock is heading for its worst week ever after an FDA panel setback for deramiocel.
FDA advisers viewed the upper-limb data for deramiocel more favorably.
Retail bulls see a possible path to FDA approval if it is narrowed to upper-limb benefits.
The stock decline follows the negative FDA panel review of deramiocel.
Investors are assessing a narrower approval scenario for the therapy.
Story angle
Center-right
L
CL
C
CR
R
Mostly straight facts, with a light government- or market-friendly tilt.
About how the story is framed, not whether the facts are true.
Asianet Newsable
Center-right
Mixed factuality
Who owns this?
Asianet News Network
Rajeev Chandrasekhar / Jupiter Capital interests historically